pembrolizumab plus chemotherapy show efficacy for tnbc in keynote-355
Published 4 years ago • 234 plays • Length 2:00Download video MP4
Download video MP3
Similar videos
-
1:30
keynote-355: hrqol unaffected by the addition of pembrolizumab to chemotherapy for tnbc
-
12:45
keynote-355: first-line pembrolizumab plus chemotherapy for metastatic triple-negative breast ca...
-
2:07
keynote-355: pembrolizumab in triple-negative breast cancer
-
3:18
#esmo21 highlights on combination of pembrolizumab plus chemotherapy in mtnbc: the keynote-355 study
-
4:49
keynote-355: pembro chemo in triple-negative breast cancer
-
4:11
asco 2020: pembrolizumab plus chemotherapy for patients with metastatic triple-negative breast c...
-
4:01
keynote-355: outcomes in pts discontinuing chemo before pembro and in pts with immune-mediated aes
-
3:34
neoadjuvant pembrolizumab plus chemo followed by adjuvant pembrolizumab shows improvement in os
-
5:01
keynote-522: final os findings of pembrolizumab and chemotherapy in tnbc
-
2:34
esmo 2021 breast cancer highlights: tulip and keynote-355
-
4:11
immunotherapy for tnbc: impassion130 & keynote-355
-
10:14
asco: pembrolizumab plus chemotherapy for advanced triple-negative breast cancer
-
4:20
keynote-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
-
1:07
phase ii results for pembrolizumab monotherapy in metastatic tnbc
-
4:54
keynote-522 updates: pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast...
-
4:53
chemoimmunotherapy in tnbc: the keynote-355 trial
-
5:34
secondary endpoints from a trial of pembrolizumab plus chemotherapy for metastatic tnbc
-
1:39:18
expanding the benefits of checkpoint inhibitors and targeted agents in triple-negative breast cancer
-
1:35
longer overall survival in metastatic tnbc with pembrolizumab - medpage today